Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED-Initiated Medications for Alcohol Use Disorder
NCT05827159Phase 3Recruiting
- Sponsor
- Yale University
- Start
- Aug 2024
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of naltrexone and gabapentin in alcohol use disorder (AUD) (2 arms), sponsored by Yale University. Primary endpoint: Participation in AUD Treatment at 30 days. Started Aug 2024; status: recruiting.
02
Drugs
naltrexonegabapentin
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT05827159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05827159.